Commercial Performance & Strategy - RYTELO's U S commercial success is the company's top priority[10, 45] - The estimated 2025 U S RYTELO total addressable LR-MDS patient population is approximately 15,400[16] - Approximately 85% of covered lives are under plans with favorable RYTELO coverage policies[27] - Since approval, approximately 900 accounts have placed orders, with approximately 300 new accounts since January 2025[26] - Approximately 25% of RYTELO new patient starts are in the 1st and 2nd line settings[26] - The company plans to commercialize RYTELO in select EU4 countries starting in 2026, pending strong reimbursement and favorable pricing[29] Clinical Development - The IMpactMF Phase 3 trial is 85% enrolled, with interim analysis anticipated in the second half of 2026[36, 38, 47] Financial Update - As of March 31, 2025, the company's cash and marketable securities were approximately $457 5 million[43] - Q1 2025 net product revenue was $39 4 million[43] - Total net product revenue since launch (June 2024) is $115 9 million[43] - The company expects total operating expenses for 2025 to range from $270 million to $285 million[43]

Company Overview - Geron Corp. is a single-product biotech company that launched an infusion drug, Imetelstat, in June 2024 for the treatment of myelodysplastic syndrome (MDS) [1] - The company is also developing Imetelstat for a second cancer indication, myelofibrosis [1] Leadership and Expertise - The executive has over 10 years of experience in the biotechnology and healthcare industry, along with 15 years of biomedical research experience [1] - The executive has served as Investment Director at a major VC&PE fund in Russia, focusing on life sciences, and has been on the Board of Directors for several biotech startups in the US and Russia [1] - The executive's background includes academic appointments at the University of Pittsburgh and Russian State Medical University, with over 50 peer-reviewed publications [1] Product Development and Strategy - The company emphasizes a systematic analysis approach to estimate risks, clinical values, and commercial prospects of innovative projects [1] - The goal is to improve patients' lives by designing new medicines and translating ideas into commercially viable products [1]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Geron Corporation due to a class action complaint alleging breaches of fiduciary duties by the board of directors during a specified class period [1][2]. Group 1: Legal Investigation - A class action complaint was filed against Geron Corporation on March 14, 2025, with a class period from February 28, 2024, to February 25, 2025 [1]. - The investigation focuses on whether Geron's board of directors failed to fulfill their fiduciary responsibilities to the company [1]. Group 2: Allegations in the Complaint - The complaint alleges that Geron's executives provided misleading information regarding the launch and growth potential of Rytelo (imetelstat) [2]. - It is claimed that the executives expressed confidence in addressing the unmet need for Rytelo while downplaying risks related to monitoring requirements and competition [2].

Core Viewpoint - Geron Corporation is facing a class action lawsuit due to alleged misleading statements regarding its revenue outlook and the market potential of its drug Rytelo, leading to significant stock price decline after disappointing financial results were announced [3][4]. Group 1: Class Action Details - The class action lawsuit represents investors who purchased Geron securities between February 28, 2024, and February 25, 2025 [1]. - Investors are encouraged to contact the Portnoy Law Firm for a complimentary case evaluation and to discuss their legal rights [2]. Group 2: Allegations Against Geron - The lawsuit claims that Geron misrepresented its revenue projections and growth potential, downplaying risks related to seasonality and macroeconomic conditions [3]. - It is alleged that Geron's optimistic portrayal of Rytelo's launch was overstated, with actual market conditions affecting patient uptake more than indicated [3]. - The company failed to achieve significant market penetration for Rytelo, particularly among first-line patients, due to limited awareness and competitive pressures [3]. Group 3: Financial Impact - On February 26, 2025, Geron reported stagnant growth for Rytelo, attributing this to seasonality, competition, and monitoring burdens, which led to a stock price drop of over 32% [4].

NEW YORK, May 12, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Geron Corporation (NASDAQ: GERN).Shareholders who purchased shares of GERN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/geron-corporation-loss-submission-form/?id=147709&from=4CLASS PERIOD: February 28, 2024 ...

With a background as an RN and an MBA, Stephen analyzes healthcare and tech stocks by combining clinical insight with rigorous valuation methods. He specializes in scenario-based DCF modeling, sensitivity analysis, and Monte Carlo simulations to uncover asymmetric risk-reward. His focus is on translating complex science and market dynamics into actionable investment theses. His influences include Superforecasting and Fooled by Randomness.Stay up to date with Stephen's latest thoughts and investment insights ...

NEW YORK, May 9, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Geron Corporation ("Geron" or the "Company") (NASDAQ: GERN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Geron investors who were adversely affected by alleged securities fraud between February 28, 2024 and February 25, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/geron-corporation-lawsuit-submissi ...

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Geron Corporation ("Geron" or the "Company") (NASDAQ: GERN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Geron investors who were adversely affected by alleged securities fraud between February 28, 2024 and February 25, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/geron-corporation-lawsuit-s ...

SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Geron Corporation (NASDAQ: GERN) securities between February 28, 2024 and February 25, 2025, all dates inclusive (the “Class Period”), have until this Monday, May 12, 2025 to seek appointment as lead plaintiff of the Geron class action lawsuit. Captioned Dabestani v. Geron Corporation, No. 25-cv-02507 (N.D. Cal.), the Geron class action lawsuit charges Geron as well as certain of Geron’s to ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 _________________________________________________________ FORM 10-Q _________________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-20859 GERO ...